CO4910149A1 - Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoceptores - Google Patents
Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoceptoresInfo
- Publication number
- CO4910149A1 CO4910149A1 CO97068609A CO97068609A CO4910149A1 CO 4910149 A1 CO4910149 A1 CO 4910149A1 CO 97068609 A CO97068609 A CO 97068609A CO 97068609 A CO97068609 A CO 97068609A CO 4910149 A1 CO4910149 A1 CO 4910149A1
- Authority
- CO
- Colombia
- Prior art keywords
- unsubstituted
- hydrogen
- imidazolinylamino
- alkylthio
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos que tienenla siguiente estructura: en donde:a) R1 es hidrógeno; o alquilo; el enlace (a) es un enlace individual o un enlace doble; b) R2 y R3 cada uno se selecciona independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituidos; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1 -C3 insustituido; tio; nitro; ciano; amino, alquilamino C1 -C3 o dialquilamino C1 -C3 y halo; c) R4 , R5 y R6 cada uno se selecciona independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino; halo; y 2-imidazolinilamino; en donde uno y solamente uno de R4 , R5 y R6 es 2-imidazolinilamino; d) R7 se selecciona independientemente de hidrógeno, alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1 -C3 y halo; e) el compuesto no es 4-(2-imidazolinilamino)indol; y enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sales de adición, amidas, y ésteres biohidrolizables, y composiciones farmacéuticas que contienen tales nuevos compuestos, y el uso de tales compuestos para prevenir o tratar transtornos modulados por alfa-2 adrenoceptores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3177796P | 1996-11-25 | 1996-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4910149A1 true CO4910149A1 (es) | 2000-04-24 |
Family
ID=21861336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97068609A CO4910149A1 (es) | 1996-11-25 | 1997-11-24 | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoceptores |
Country Status (23)
Country | Link |
---|---|
US (2) | US6162818A (es) |
EP (1) | EP0944621B1 (es) |
JP (1) | JP2001506981A (es) |
KR (1) | KR100395356B1 (es) |
CN (1) | CN1092652C (es) |
AR (1) | AR013875A1 (es) |
AT (1) | ATE275142T1 (es) |
AU (1) | AU735767B2 (es) |
BR (1) | BR9713542A (es) |
CA (1) | CA2271841C (es) |
CO (1) | CO4910149A1 (es) |
CZ (1) | CZ180599A3 (es) |
DE (1) | DE69730516T2 (es) |
ES (1) | ES2225998T3 (es) |
HU (1) | HUP9904215A3 (es) |
ID (1) | ID22812A (es) |
IL (1) | IL130024A (es) |
NO (1) | NO992470L (es) |
PE (1) | PE16299A1 (es) |
SK (1) | SK68399A3 (es) |
TR (1) | TR199901885T2 (es) |
WO (1) | WO1998023610A1 (es) |
ZA (1) | ZA9710577B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
TR199901885T2 (xx) * | 1996-11-25 | 1999-10-21 | The Procter & Gamble Company | Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri. |
US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
JP2003505369A (ja) * | 1999-07-15 | 2003-02-12 | エヌピーエス アレリックス コーポレーション | 偏頭痛を治療するための複素環式化合物 |
AU2042301A (en) * | 1999-12-03 | 2001-06-12 | Alcon Universal Limited | 1-aminoalkyl-1H-indoles for treating glaucoma |
US20030166732A1 (en) * | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
NZ537200A (en) * | 2002-06-24 | 2007-09-28 | Schering Corp | Indole piperidine derivatives useful as histamine H3 antagonists |
KR20050072812A (ko) | 2002-11-07 | 2005-07-12 | 악조 노벨 엔.브이. | 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌 |
DE10332473A1 (de) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Epilepsie |
TW200602317A (en) | 2004-04-23 | 2006-01-16 | Akzo Nobel Nv | Novel androgens |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
CL2008000838A1 (es) * | 2007-03-23 | 2008-10-10 | Neuraxon Inc | Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US20100029662A1 (en) * | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Vasoconstriction compositions and methods of use |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20100196286A1 (en) * | 2008-12-01 | 2010-08-05 | Armer Thomas A | Inhalation delivery methods and devices |
WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
CH632268A5 (de) * | 1977-01-14 | 1982-09-30 | Sandoz Ag | Verfahren zur herstellung von neuen heterocyclylaminoderivaten. |
US4398028A (en) * | 1977-01-14 | 1983-08-09 | Sandoz Ltd. | Bicyclic heterocyclic amino derivatives |
US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
TR199901885T2 (xx) * | 1996-11-25 | 1999-10-21 | The Procter & Gamble Company | Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri. |
-
1997
- 1997-11-21 TR TR1999/01885T patent/TR199901885T2/xx unknown
- 1997-11-21 HU HU9904215A patent/HUP9904215A3/hu unknown
- 1997-11-21 BR BR9713542-9A patent/BR9713542A/pt not_active IP Right Cessation
- 1997-11-21 WO PCT/US1997/020801 patent/WO1998023610A1/en not_active Application Discontinuation
- 1997-11-21 CN CN97180036A patent/CN1092652C/zh not_active Expired - Fee Related
- 1997-11-21 AU AU54380/98A patent/AU735767B2/en not_active Ceased
- 1997-11-21 SK SK683-99A patent/SK68399A3/sk unknown
- 1997-11-21 ES ES97948289T patent/ES2225998T3/es not_active Expired - Lifetime
- 1997-11-21 IL IL13002497A patent/IL130024A/en not_active IP Right Cessation
- 1997-11-21 KR KR10-1999-7004535A patent/KR100395356B1/ko not_active IP Right Cessation
- 1997-11-21 ID IDW990403D patent/ID22812A/id unknown
- 1997-11-21 JP JP52469398A patent/JP2001506981A/ja active Pending
- 1997-11-21 EP EP97948289A patent/EP0944621B1/en not_active Expired - Lifetime
- 1997-11-21 CA CA002271841A patent/CA2271841C/en not_active Expired - Fee Related
- 1997-11-21 CZ CZ991805A patent/CZ180599A3/cs unknown
- 1997-11-21 AT AT97948289T patent/ATE275142T1/de not_active IP Right Cessation
- 1997-11-21 DE DE69730516T patent/DE69730516T2/de not_active Expired - Lifetime
- 1997-11-24 CO CO97068609A patent/CO4910149A1/es unknown
- 1997-11-25 PE PE1997001069A patent/PE16299A1/es not_active Application Discontinuation
- 1997-11-25 AR ARP970105526A patent/AR013875A1/es unknown
- 1997-11-25 ZA ZA9710577A patent/ZA9710577B/xx unknown
-
1999
- 1999-04-13 US US09/290,731 patent/US6162818A/en not_active Expired - Lifetime
- 1999-05-21 NO NO992470A patent/NO992470L/no not_active Application Discontinuation
-
2000
- 2000-10-17 US US09/690,992 patent/US6395764B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HUP9904215A3 (en) | 2002-01-28 |
EP0944621A1 (en) | 1999-09-29 |
ID22812A (id) | 1999-12-09 |
NO992470L (no) | 1999-07-26 |
ES2225998T3 (es) | 2005-03-16 |
US6395764B1 (en) | 2002-05-28 |
TR199901885T2 (xx) | 1999-10-21 |
IL130024A (en) | 2002-12-01 |
CN1092652C (zh) | 2002-10-16 |
KR20000069088A (ko) | 2000-11-25 |
DE69730516D1 (de) | 2004-10-07 |
ATE275142T1 (de) | 2004-09-15 |
US6162818A (en) | 2000-12-19 |
IL130024A0 (en) | 2000-02-29 |
JP2001506981A (ja) | 2001-05-29 |
AU735767B2 (en) | 2001-07-12 |
AR013875A1 (es) | 2001-01-31 |
AU5438098A (en) | 1998-06-22 |
DE69730516T2 (de) | 2005-09-01 |
CN1238771A (zh) | 1999-12-15 |
EP0944621B1 (en) | 2004-09-01 |
HUP9904215A2 (hu) | 2000-06-28 |
SK68399A3 (en) | 2000-07-11 |
CA2271841C (en) | 2003-07-08 |
NO992470D0 (no) | 1999-05-21 |
KR100395356B1 (ko) | 2003-08-21 |
WO1998023610A1 (en) | 1998-06-04 |
CA2271841A1 (en) | 1998-06-04 |
PE16299A1 (es) | 1999-03-12 |
ZA9710577B (en) | 1998-06-25 |
CZ180599A3 (cs) | 1999-11-17 |
BR9713542A (pt) | 2000-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4910149A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoceptores | |
CO4910148A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonis- tas de alfa-2 adrenoceptores | |
AR002955A1 (es) | Un compuesto heterocíclico substituido, procedimiento y compuestos intermediarios para su preparación y composición farmacéutica que contiene a dicho compuesto. | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
UY27522A1 (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
CO5160347A1 (es) | Derivados de acido carbamico | |
CO4970702A1 (es) | Quinolonas antimicrobianas, sus composiciones y sus usos | |
TR200000671T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler. | |
TR200000670T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
AR002690A1 (es) | Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado. | |
AR026352A1 (es) | Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii. | |
TR200000673T2 (tr) | FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. | |
UY24482A1 (es) | Quinoxalinadionas | |
AR022019A1 (es) | Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen | |
CO4910150A1 (es) | Compuestos de 2-imidazolinilaminobenzoxazol utiles con agonistas de alfa-2 adrenoceptores | |
NZ513594A (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors | |
ES2177816T3 (es) | Derivados de azahexano como isosteros de sustrato de aspartato proteasas retroviricas. | |
ES2249636T3 (es) | Triazoles como antagonistas de la oxitocina. | |
CO4910166A1 (es) | Compuestos 2-imidazolinilaminoindazol utiles como agonistas de 2-alfa adrenoceptores | |
BR0109348A (pt) | Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas | |
CO4910168A1 (es) | Compuestos de 2-imidazolinilaminobenzotiazol utiles como agonistas de alfa-2 adrenoceptores | |
AR035765A1 (es) | Composiciones fungicidas de n-2-piridinilmetilbenzamida y del propil ester de acido (3-(dimetilamino)-propil) carbamico; procedimientos curativos o preventivos contra hongos fitopatogenos de cultivos, utilizando dichas composiciones y productos de aplicacion combinada, simultanea, separada o secuenc | |
ECSP045200A (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos | |
AR009144A1 (es) | Compuestos heterociclicos guanidilamino, composicion farmaceutica que comprende dicho compuesto y uso del mismo para la fabricacion de un medicamento |